Gradient Investments buys $4,920,812 stake in Amgen (AMGN)

Amgen (AMGN) : Gradient Investments scooped up 3,801 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 14, 2016. The investment management firm now holds a total of 30,202 shares of Amgen which is valued at $4,920,812.Amgen makes up approximately 0.52% of Gradient Investments’s portfolio.

Other Hedge Funds, Including , Balasa Dinverno Foltz boosted its stake in AMGN in the latest quarter, The investment management firm added 160 additional shares and now holds a total of 6,024 shares of Amgen which is valued at $981,490. Amgen makes up approx 0.17% of Balasa Dinverno Foltz’s portfolio.Chevy Chase Trust Holdings boosted its stake in AMGN in the latest quarter, The investment management firm added 215 additional shares and now holds a total of 677,575 shares of Amgen which is valued at $109,157,333. Amgen makes up approx 0.60% of Chevy Chase Trust Holdings’s portfolio.Marshwinds Advisory Co reduced its stake in AMGN by selling 790 shares or 2.77% in the most recent quarter. The Hedge Fund company now holds 27,740 shares of AMGN which is valued at $4,468,914. Amgen makes up approx 2.16% of Marshwinds Advisory Co’s portfolio.Stock Yards Bank Trust Co reduced its stake in AMGN by selling 25,379 shares or 62.44% in the most recent quarter. The Hedge Fund company now holds 15,267 shares of AMGN which is valued at $2,355,240. Amgen makes up approx 0.31% of Stock Yards Bank Trust Co’s portfolio.

Amgen closed down -0.35 points or -0.21% at $162.93 with 18,15,610 shares getting traded on Monday. Post opening the session at $163.82, the shares hit an intraday low of $162.79 and an intraday high of $164 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.